Clinical Trial

Aldosterone Identifies a High-Risk Recurrent Phenotype in Severe Hypertension

Study acronym: VATAHTA-ACUTE
Completed
View on ClinicalTrials.gov →
Summary
Acute severe hypertension is a common and heterogeneous clinical condition associated with significant short-term morbidity and health care utilization. Despite its frequency, underlying pathophysiological mechanisms remain poorly characterized, particularly regarding the role of aldosterone dysregulation beyond classical primary aldosteronism. The VATAHTA Acute Study is an observational cohort study designed to evaluate the association between aldosterone levels, renin profiles, and clinical outcomes in patients presenting with acute severe hypertension requiring hospital admission. The study aims to characterize a potential spectrum of aldosterone dysregulation and its relationship with short-term clinical severity, including length of hospital stay, target organ damage, and cardiovascular events. By integrating clinical, biochemical, and outcome data, this study seeks to improve the understanding of pathophysiological phenotypes in acute severe hypertension and identify potential targets for risk stratification and future therapeutic strategies.
Trial Details
NCT Number NCT07535814
Lead Sponsor School of Medicine. National University of Cuyo
Collaborators: Hospiral Español de Mendoza
Conditions Acute Severe Hypertension
Enrollment 500 participants
Start Date 2022-03-01
Primary Completion 2025-12-20 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-17